Endometrial cancer is a clinically heterogeneous disease and it is becoming increasingly
clear that this heterogeneity may be a function of the diversity of the underlying molecular …

Endometrial cancer is the most common gynaecological malignancy in high income
countries and its incidence is rising. Whilst most women with endometrial cancer are …

A European consensus conference on endometrial carcinoma was held in 2014 to produce
multi-disciplinary evidence-based guidelines on selected questions. Given the large body of …

Endometrial cancer is the most common gynecological malignancy in high‐and middle‐
income countries. Although the overall prognosis is relatively good, high‐grade endometrial …

Background PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR)
endometrial cancer, comparing pelvic external beam radiotherapy (EBRT) with vaginal …

Introduction The clinical role of the molecular endometrial cancer (EC) classification has not
been fully explored in patients staged with lymphadenectomy or without adjuvant treatment …

Endometrial cancer is the most common gynecological malignancy in high‐income
countries. Although the overall prognosis is relatively good, high‐grade endometrial cancers …

Abstract Objective The Post-Operative Radiation Therapy in Endometrial Carcinoma
(PORTEC)-4a trial is a randomized trial for women with high-intermediate risk endometrial …

Our understanding of endometrial cancer has evolved through improvements in molecular
biology, allowing improved definition of target-specific therapies. The precise role and …

Objective Our aim was to characterize the pathological, molecular and clinical outcomes of
clear cell carcinoma of the endometrium (CCC). Methods CCC underwent ProMisE …